Name | Lenalidomide |
Synonyms | CC-5013 Revlimi Revlimid enalidomide Lenalidomid Lenalidomide LenalidoMide(CC-5013,RevliMid) Lenalidomide(other anti-cancers) 1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(7-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione,Lenalidomide 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione |
CAS | 191732-72-6 |
EINECS | 691-297-1 |
InChI | InChI=1/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18) |
Molecular Formula | C13H13N3O3 |
Molar Mass | 259.26 |
Density | 1.460±0.06 g/cm3(Predicted) |
Melting Point | 265-268 °C |
Boling Point | 614.0±55.0 °C(Predicted) |
Flash Point | 325.1°C |
Solubility | Soluble in DMSO (≥52 mg/ml) at 25 °C, methanol and water (2: 1), buffered aqueous sol |
Vapor Presure | 5.2E-15mmHg at 25°C |
Appearance | Solid |
Color | White |
pKa | 10.75±0.40(Predicted) |
Storage Condition | 2-8°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
Refractive Index | 1.672 |
Use | A Thalidomide analog known to have immunomodulatory properties |
In vitro study | CC-5013 strong induction IL-2 and sIL-2R yield. CC-5013 acts on T cells to induce tyrosine phosphorylation of CD28 and subsequently down-regulate activation of NF-κB. Lenalidomide and Pomalidomide act on HEK293 T cells expressing wild-type CRBN bound to Thalidomide, but not Thalidomide bound to defective CRBN(YW/AA), to inhibit CRBN autoubiquitination. In KMS12 multiple myeloma cells, overexpression of the CRBN wild-type protein but not the CRBN(YW/AA) mutant protein amplifies Pomalidomide-regulated c-myc and decreases in IRF4 expression and increases in p21(WAF-1) expression. The selectivity of long-term resistance to Lenalidomide in H929 multiple myeloma cell lines was associated with decreased CRBN, whereas no CRBN protein was detected in DF15R multiple myeloma resistant to Pomalidomide and Lenalidomide. Lenalidomide inhibits the development of defects by down-regulating the expression of tumor cell inhibitory molecules. Lenalidomide prevents tumor-induced T-cell lytic dysfunction from occurring. Lenalidomide acts on T cells to inhibit chronic lymphocytic leukemia (CLL) cell-induced impairment of T cell actin synaptic function, and down-regulates CLL to inhibit the expression of ligands and other receptors. Lenalidomide acts on FL, DLBCL, HL, MM, SCC, and OC, inhibits tumor-induced immunosuppression, and down-regulates immunosuppressive ligand expression when it acts on all tumor cells tested. |
In vivo study | Oral treatment of Lenalidomide significantly inhibited bFGF-induced angiogenesis in a dose-dependent manner. Lenalidomide significantly reduced percent vascular area from 5.16 percent in the control group to 2.58(50 mg/kg treatment) and 1.69(250 mg/kg treatment) in the experimental group. Lenalidomide significantly reduced overall MVL from 21.07 in the control group to 8.11(50 mg/kg dose treatment) and 1.90(250 mg/kg dose treatment) in the experimental group. |
Risk Codes | 20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. |
Safety Description | 36/37 - Wear suitable protective clothing and gloves. |
HS Code | 29339900 |
Hazard Class | IRRITANT |